ANNEXON, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ANNEXON, INC. (ANNX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $5.14 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- ANNEXON, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $5.26, a 103.09% increase year-over-year.
- ANNEXON, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $2.59, a 49.51% decline year-over-year.
- ANNEXON, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $5.13, a 15.21% decline year-over-year.
- ANNEXON, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $6.05, a 11.29% decline year-over-year.
- ANNEXON, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $2.56, a 55.32% decline from fiscal 2024.
- ANNEXON, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $5.73, a 10.83% increase from fiscal 2023.
- ANNEXON, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $5.17, a 7.51% decline from fiscal 2022.
- ANNEXON, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $5.59, a 78.11% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.14 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $5.26 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $2.56 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $2.55 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $2.55 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $2.59 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | $5.73 10-K · filed 2025-03-03 | |||
| 2024-09-30 | $5.70 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $5.26 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $5.13 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $5.17 10-K · filed 2024-03-26 | |||
| 2023-09-30 | $5.39 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $5.82 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $6.05 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $5.59 10-K · filed 2023-03-06 | |||
| 2022-09-30 | $5.59 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $6.06 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $6.82 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $25.54 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $26.32 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $28.09 10-Q · filed 2021-08-16 | |||
| 2021-03-31 | $29.81 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | $16.88 10-K · filed 2021-03-25 | |||
| 2020-09-30 | $14.77 10-Q · filed 2020-11-16 | |||
| 2020-06-30 | $13.39 10-Q · filed 2020-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |